ArticleAntimicrobial agents and chemotherapy2004
Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 65 citations in OpenAlex.
- A Mouse Model of MildMicroorganisms · 2024Article
- A High-Carbohydrate Diet Prolongs Dysbiosis and Clostridioides difficile Carriage and Increases Delayed Mortality in a Hamster Model of Infection.Microbiology spectrum · 2022Article
- Application of recombinant antibodies for treatment ofFrontiers in immunology · 2022Review
- In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection.Scientific reports · 2021Article
- The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.Cell reports. Medicine · 2020Article
- Effect of the Synthetic Bile Salt Analog CamSA on the Hamster Model of Clostridium difficile Infection.Antimicrobial agents and chemotherapy · 2018Article
- Establishment of an EndogenousFrontiers in microbiology · 2018Article
- A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.Infectious diseases and therapy · 2017Review
- Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection.The Journal of antimicrobial chemotherapy · 2015Article
- Clostridium difficile drug pipeline: challenges in discovery and development of new agents.Journal of medicinal chemistry · 2015Review
- The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.Molecular immunology · 2015Review
- Clinical update for the diagnosis and treatment of Clostridium difficile infection.World journal of gastrointestinal pharmacology and therapeutics · 2014Review
- Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Current topics in medicinal chemistry · 2014Review
- Clostridium difficile infection: molecular pathogenesis and novel therapeutics.Expert review of anti-infective therapy · 2014Review
- The potential for emerging therapeutic options for Clostridium difficile infection.Gut microbes · 2014Review
- The membrane as a target for controlling hypervirulent Clostridium difficile infections.The Journal of antimicrobial chemotherapy · 2013Article
- In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.Antimicrobial agents and chemotherapy · 2012Article
- MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.Antimicrobial agents and chemotherapy · 2012Article
- Efficacy of LFF571 in a hamster model of Clostridium difficile infection.Antimicrobial agents and chemotherapy · 2012Article
- The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity.Antimicrobial agents and chemotherapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although vancomycin and metronidazole effectively treat Clostridium difficile-associated diarrhea and colitis (CDAD), their use is associated with a high incidence of relapsing C. difficile infection. Rifalazil is a new benzoxazinorifamycin that possesses activity against Mycobacterium tuberculosis and gram-positive bacteria. Here we compared rifalazil and vancomycin for effectiveness in preventing or treating clindamycin-induced cecitis in a hamster model of CDAD. Golden Syrian hamsters were injected subcutaneously with clindamycin phosphate (10 mg/kg), followed 24 h later by C. difficile gavage. Hamsters received by gavage for 5 days vehicle, vancomycin (50 mg/kg), or rifalazil (20 mg/kg) either simultaneously with (prophylactic protocol) or 24 h after C. difficile administration (treatment protocol). While all vehicle-administered animals became moribund within 48 h of C. difficile administration, no rifalazil- or vancomycin-treated animals in either protocol showed signs of morbidity after 7 days. Ceca of rifalazil-treated animals showed absence of epithelial cell damage, significantly reduced congestion and edema, and less, but not statistically significantly less, neutrophil infiltration compared to those of vehicle-treated animals. In contrast, vancomycin-treated animals demonstrated severe epithelial cell damage and mildly reduced congestion and edema. Moreover, hamsters relapsed and tested C. difficile toxin positive (by enzyme-linked immunosorbent assay) 10 to 15 days after discontinuation of vancomycin treatment. None of the rifalazil-treated hamsters showed signs of disease or presence of toxins in their feces 30 days after discontinuation of treatment. Our results indicate that once daily rifalazil may be superior to vancomycin for curative treatment of CDAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.